Table 2.
Unadjusted Estimates of Survival from Time of Recurrence after Completing Definitive Therapy for Stage I–III Breast, Colorectal, or Lung Cancer**
| Recurrent Breast Cancer | Recurrent Colorectal Cancer | Recurrent Lung Cancer | |||||||
|---|---|---|---|---|---|---|---|---|---|
| RMST through 60 months (months) |
Median survival (months) |
2-year survival (%) |
RMST through 60 months (months) |
Median survival (months) |
2-year survival (%) |
RMST through 60 months (months) |
Median survival (months) |
2-year survival (%) |
|
| Overall | 28.4 | 21.2 | 47 | 23.1 | 16.6 | 37 | 16.1 | 8.8 | 21 |
|
| |||||||||
| Age at recurrence | |||||||||
|
| |||||||||
| 21–54 | 30.9 | 25.0 | 51 | 29.2 | 23.0 | 46 | 21.1 | 14.9 | 31 |
| 55–69 | 28.9 | 22.1 | 48 | 26.1 | 19.1 | 42 | 16.8 | 8.2 | 21 |
| ≥70 | 25.0 | 16.8 | 41 | 18.3 | 12.1 | 29 | 14.4 | 8.5 | 18 |
|
| |||||||||
| Sex | |||||||||
|
| |||||||||
| Male | NA | NA | NA | 23.9 | 17.9 | 39 | 15.8 | 9.3 | 19 |
| Female | 28.4 | 21.2 | 47 | 22.1 | 14.6 | 34 | 16.4 | 8.2 | 22 |
|
| |||||||||
| Race/Ethnicity | |||||||||
|
| |||||||||
| Non-Hispanic white | 28.1 | 20.8 | 46 | 22.9 | 15.6 | 37 | 15.9 | 8.5 | 20 |
| Non-White or Hispanic | 31.6 | 34.2 | 53 | 23.6 | 19.1 | 38 | 16.9 | 10.9 | 24 |
|
| |||||||||
| Marital status | |||||||||
|
| |||||||||
| Married/living with partner | 29.1 | 22.8 | 48 | 24.5 | 18.7 | 40 | 16.1 | 9.5 | 20 |
| Not married | 27.0 | 17.1 | 44 | 20.6 | 12.6 | 32 | 16.1 | 8.1 | 22 |
|
| |||||||||
| Smoking status | |||||||||
|
| |||||||||
| Never | 29.8 | 21.4 | 48 | 23.4 | 16.7 | 38 | 23.4 | 15.8 | 42 |
| Former | 25.9 | 18.3 | 41 | 22.5 | 16.7 | 35 | 15.6 | 8.7 | 20 |
| Current | 28.3 | 25.0 | 52 | 23.9 | 15.8 | 37 | 14.5 | 8.2 | 14 |
|
| |||||||||
| Annual income (US$) –census block† | |||||||||
|
| |||||||||
| <40,000 | 27.4 | 21.2 | 42 | 22.7 | 15.7 | 39 | 14.4 | 8.0 | 16 |
| 40,000 to <60,000 | 28.8 | 25.0 | 50 | 22.2 | 13.7 | 34 | 13.8 | 5.7 | 17 |
| ≥60,000 | 28.4 | 20.2 | 46 | 23.6 | 17.7 | 37 | 16.7 | 10.7 | 20 |
|
| |||||||||
| Annual income (US$) – self-report‡ | |||||||||
|
| |||||||||
| <40,000 | -- | -- | -- | 21.4 | 14.6 | 34 | 15.0 | 8.6 | 19 |
| 40,000 to <60,000 | -- | -- | -- | 23.8 | 20.2 | 40 | 16.7 | 12.3 | 20 |
| ≥60,000 | -- | -- | -- | 27.2 | 22.9 | 47 | 22.3 | 13.5 | 34 |
|
| |||||||||
| Data Source | |||||||||
|
| |||||||||
| CRN | 28.4 | 21.2 | 47 | 23.0 | 15.8 | 36 | 15.4 | 8.2 | 18 |
| CanCORS | NA | NA | NA | 23.2 | 16.8 | 38 | 16.6 | 9.3 | 22 |
|
| |||||||||
| Modified Charlson comorbidity index | |||||||||
|
| |||||||||
| 0 | 30.2 | 24.3 | 51 | 25.5 | 19.3 | 41 | 19.8 | 13.5 | 28 |
| 1 | 27.6 | 16.8 | 43 | 20.9 | 15.8 | 34 | 15.6 | 8.0 | 20 |
| 2+ | 17.0 | 8.9 | 23 | 18.7 | 8.9 | 27 | 12.7 | 7.5 | 14 |
|
| |||||||||
| Year of recurrence | |||||||||
|
| |||||||||
| 2000–2003 | 22.1 | 12.4 | 30 | 16.7 | 8.1 | 24 | 10.4 | 5.0 | 9 |
| 2004–2006 | 30.0 | 22.8 | 50 | 23.0 | 16.3 | 37 | 17.3 | 9.6 | 23 |
| 2007–2009 | 29.9 | 24.4 | 50 | 26.0 | 19.9 | 43 | 15.8 | 8.8 | 19 |
| 2010–2012 | 28.3 | 20.8 | 49 | 25.0 | 19.9 | 37 | 14.8 | 8.2 | 20 |
|
| |||||||||
| Stage of primary diagnosis | |||||||||
|
| |||||||||
| I | 39.2 | 49.1 | 66 | 31.5 | 30.3 | 53 | 17.3 | 11.6 | 23 |
| II | 26.5 | 18.6 | 45 | 25.4 | 16.5 | 44 | 16.4 | 8.0 | 22 |
| III | 20.4 | 16.7 | 31 | 20.4 | 15.4 | 30 | 12.9 | 6.8 | 14 |
|
| |||||||||
| Primary cancer HR status | |||||||||
|
| |||||||||
| HR negative | 22.9 | 13.7 | 33 | NA | NA | NA | NA | NA | NA |
| HR positive | 30.7 | 26.3 | 53 | NA | NA | NA | NA | NA | NA |
|
| |||||||||
| Primary cancer grade | |||||||||
|
| |||||||||
| Low/Intermediate | 32.4 | 31.0 | 56 | 24.9 | 19.3 | 41 | 18.2 | 13.3 | 27 |
| High/Undifferentiated | 24.8 | 16.3 | 39 | 17.2 | 9.2 | 23 | 14.2 | 7.0 | 15 |
|
| |||||||||
| Chemotherapy for the primary cancer | |||||||||
|
| |||||||||
| No | 33.3 | 34.9 | 56 | 23.2 | 13.9 | 38 | 16.3 | 9.5 | 21 |
| Yes | 26.4 | 19.0 | 43 | 23.1 | 17.7 | 36 | 15.7 | 8.1 | 20 |
|
| |||||||||
| Radiation therapy for the primary cancer | |||||||||
|
| |||||||||
| No | 32.3 | 25.0 | 52 | 22.3 | 15.6 | 35 | 16.8 | 9.6 | 22 |
| Yes | 26.4 | 19.8 | 44 | 25.5 | 19.9 | 42 | 14.0 | 6.7 | 17 |
|
| |||||||||
| Time from primary to recurrence (years) | |||||||||
|
| |||||||||
| 0 to 1 | 21.9 | 12.6 | 33 | 21.2 | 12.9 | 31 | 14.7 | 6.9 | 19 |
| >1 to 2 | 26.7 | 18.0 | 40 | 23.7 | 18.3 | 40 | 16.7 | 10.9 | 20 |
| >2 to 4 | 27.4 | 21.0 | 46 | 25.3 | 19.6 | 40 | 18.1 | 11.2 | 26 |
| >4 for breast | 35.3 | 36.9 | 67 | 21.3 | 15.7 | 36 | 15.6 | 9.8 | 20 |
|
| |||||||||
| Type of recurrence | |||||||||
|
| |||||||||
| Local | 49.3 | 84.2 | 82 | 43.0 | 63.6 | 77 | 17.3 | 11.2 | 16 |
| Distant or regional | 23.5 | 17.1 | 38 | 21.5 | 15.6 | 34 | 16.0 | 8.5 | 21 |
|
| |||||||||
| Chemotherapy for the recurrence* | |||||||||
|
| |||||||||
| No | 37.7 | 38.6 | 63 | 26.7 | 21.8 | 44 | 19.7 | 13.6 | 26 |
| Yes | 27.7 | 20.8 | 45 | 27.3 | 20.6 | 43 | 19.6 | 12.1 | 26 |
|
| |||||||||
| Radiation therapy for the recurrence* | |||||||||
|
| |||||||||
| No | 32.8 | 28.0 | 55 | 27.3 | 21.8 | 44 | 19.4 | 13.4 | 25 |
| Yes | 29.8 | 21.5 | 49 | 21.9 | 17.5 | 37 | 20.2 | 13.3 | 26 |
Abbreviations: RMST = Restricted Mean Survival Time; CRN = Cancer Research Network; CanCORS = Cancer Care Outcomes Research & Surveillance Consortium, NA = Not applicable.
The coefficient value listed for each characteristic represents the number of additional months of survival gained or lost if that characteristic was present, relative to the reference group for that covariate. For example, a breast cancer patient with a distant/reginal recurrence had a 19.1-month shorter mean survival compared to a breast cancer patient with a local recurrence. Considering the intercept value of 66.7 months, the estimated mean survival for a patient with distant/regional recurrence was 47.6 months, assuming all of the other covariates were the reference categories. If the same breast cancer patient also had a comorbidity score of 2+, then her estimated mean survival would have been 37.6 months (= 66.7 months [intercept] −19.1 months [distant/regional recurrence] −10.0 months [2+ comorbidity]).
Among patients who survived at least 3 months after recurrence
Among CRN cohort
Among CanCORS cohort.